You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent Platinum-Sensitive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)

Completed
  • Ovarian Cancer
  • +2 more
  • Ann Arbor, Michigan
  • +7 more
Sep 1, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

Recruiting
  • Recurrent Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • Simvastatin 40mg
  • Los Angeles, California
    Cedars Sinai Medical Center
Apr 21, 2022

Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Fuzuloparib Combination with Bevacizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Cente
Apr 14, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

Recruiting
  • Recurrent Ovarian Cancer
  • +6 more
  • Durham, North Carolina
  • +2 more
Jul 26, 2022

Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer Trial in United States (Secondary Cytoreductive Surgery, Carboplatin

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Secondary Cytoreductive Surgery
  • +2 more
  • Hartford, Connecticut
  • +10 more
Feb 23, 2022

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,

Recruiting
  • Ovarian Cancer by FIGO Stage
  • +2 more
  • Oregovomab
  • +3 more
  • Daegu, Korea, Republic of
  • +5 more
Oct 20, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer Trial in France (OSE2101, Pembrolizumab 25 MG/ML [Keytruda])

Recruiting
  • Platinum-sensitive Ovarian Cancer
  • Relapsed Ovarian Cancer
  • OSE2101
  • Pembrolizumab 25 MG/ML [Keytruda]
  • Angers, France
  • +27 more
Jul 25, 2022

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor Trial in Seoul

Recruiting
  • Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Jul 6, 2021

Epithelial Ovarian Cancer Trial (Niraparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • (no location specified)
May 19, 2022

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Bespoke ctDNA Assay for Recurrence and Treatment Response

Recruiting
  • Ovarian Cancer
  • platinum-sensitive EOC
  • platinum-resistant and rEOC
  • Shanghai, Shanghai, China
    Hao Wen
Jul 5, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated

Recruiting
  • Ovarian Cancer
  • +3 more
  • ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
  • Blacktown, New South Wales, Australia
  • +5 more
Nov 9, 2022

Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer Trial in Seoul (Olaparib-Pembrolizumab-Bevacizumab)

Enrolling by invitation
  • Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
  • Seoul, Korea, Republic of
    Yonsei Severance Hospital
Apr 14, 2021

Epithelial Ovarian Cancer Trial in Singapore (Oregovomab, Nivolumab, Chemotherapy)

Unknown status
  • Epithelial Ovarian Cancer
  • Singapore, Singapore
  • +1 more
Nov 30, 2021